|
|
 |
|
|
Hello,
This week’s postings include the following items:
• July 2010 HCV Advocate Newsletter:
- “Is It Cost Effective to Treat HCV?” A recap of a study conducted by Sammy Saab and colleagues looking at the cost effectiveness of treating HCV at various stages of the disease
- EASL, Part 2 concentrating on the studies presented at EASL focusing on HCV polymerase inhibitors, NS4A inhibitors, and various all-oral combinations
- Two perspectives on postponing HCV treatment until the new combinations of pegylated interferon, ribavirin and HCV protease inhibitors become available:
- “HealthWise: Waiting for Better HCV Treatment: Living in the Gap,” and
- “Editorial: Is it Safe To Wait?”
• Other items posted to the HCV and HBV Advocate websites include:
- Hepatitis Journal Review, by Liz Highleyman
- HBV Journal Review, by Christine Kukka
- Advocate HCV News Review
- HCV Drug Pipeline - Updated June 30, 2010
Enjoy!
Alan
Join me on Twitter -
Alan Franciscus
Executive Director, Hepatitis C Support Project
Editor-in-Chief, HCV Advocate www.hcvadvocate.org
Editor-in-Chief, HBV Advocate www.hbvadvocate.org
**Questions and Comments: Questions and/or comments can be directed to alanfranciscus@hcvadvocate.org
**To receive the eblast in your email inbox simply send an e-mail to: listserv@list.hcvadvocate.org with nothing in the subject line and the following in the message body: subscribe emailalert. Make sure your email address is all lower case.
|
|
 |
|
|
